Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
150.27
-0.06 (-0.04%)
At close: Aug 15, 2025, 4:00 PM
147.27
-3.00 (-2.00%)
After-hours: Aug 15, 2025, 7:11 PM EDT
Krystal Biotech Employees
Krystal Biotech had 275 employees as of December 31, 2024. The number of employees increased by 46 or 20.09% compared to the previous year.
Employees
275
Change (1Y)
46
Growth (1Y)
20.09%
Revenue / Employee
$1,306,200
Profits / Employee
$533,545
Market Cap
4.35B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 275 | 46 | 20.09% |
| Dec 31, 2023 | 229 | 19 | 9.05% |
| Dec 31, 2022 | 210 | 91 | 76.47% |
| Dec 31, 2021 | 119 | 44 | 58.67% |
| Dec 31, 2020 | 75 | 22 | 41.51% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
KRYS News
- 11 days ago - Krystal Biotech, Inc. (KRYS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 21 days ago - Krystal Biotech Announces Approval of VYJUVEK® by Japan's Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa - GlobeNewsWire
- 22 days ago - Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté - GlobeNewsWire
- 5 weeks ago - Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis - GlobeNewsWire
- 7 weeks ago - Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa - GlobeNewsWire
- 3 months ago - Krystal Biotech to Present at BofA Securities 2025 Health Care Conference - GlobeNewsWire
- 3 months ago - Krystal Biotech, Inc. (KRYS) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa - GlobeNewsWire